- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03089229
A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis
November 5, 2018 updated by: Haus Bioceuticals
A Study to Evaluate the Efficacy and Safety of HAT01H, a Novel Topical Therapeutic: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance of epidermal-barrier function that results in intensely pruritic subacute and chronic eczematous plaques.
The current therapy of AD is reactive, where the flares are treated through symptomatic management with topical corticosteroids and calcineurin inhibitors.
Given that these medications have long-term side-effects, and given the chronically relapsing immunopathogenic nature of AD, there is an imperative need for safer anti-inflammatory medications.
Haus Bioceuticals (Haus) has developed a novel topical treatment for eczema/atopic dermatitis (AD) denoted HAT01H, and have demonstrated that HAT01H is safe and profoundly effective in the treatment of AD, controlling signs and symptoms in 85% of patients with AD.
This study is aimed to further test the efficacy and safety of topical HAT01H in patients with moderate to severe atopic dermatitis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a 13 week (91 days) randomized, double-blind, in home use study among 30 male and female subjects with moderate to severe active atopic dermatitis (AD).
The study will include subjects with ages 12 - 65 years old inclusive.
Group assignments will be balanced by age and disease severity of AD.
The study will consist of a 1 week washout period and 12 week treatment phase.
During the treatment phase, subject will be provided one of the two test products to use twice daily on all lesions and non-lesional areas as instructed.
No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Measurements, expert visual assessments and self-assessments will be taken as described below.
Safety and tolerability will be evaluated by incidence of AE's (defined per CTCAE), exacerbations, application site reactions/infections, and lab evals.
There will also be consumption/compliance checks and dermatological evaluations at each visit.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Karnataka
-
Bangalore, Karnataka, India
- Clinical Research Pvt Ltd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 65 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Moderate to severe atopic dermatitis as determined by PGA ≥ 3 and SCORAD > 25
- Males and females, age 12 - 65 years old inclusive
Exclusion Criteria:
- Is currently participating or has participated in another interventional clinical study at this or any other facility in the past 3 months.
- Currently or has been diagnosed or treated for cancer in the past 5 years.
- Requires any topical or systemic medications that could affect the course of their atopic dermatitis during the study period (except inhaled steroids and/or stable antihistamines for asthma or allergies).
- Has a known hypersensitivity to any corticosteroid creams.
- Has any active infections or has used antibiotics in the past 7 days.
- Has any physical attributes or skin conditions that might interfere with clear visual assessments (i.e. cuts, sunburn, birth marks, tattoos, extensive scarring, excessive hair growth or acne)
- Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus, rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results.
- Has used any immunosuppressant drugs or immunotherapy within the past 30 days or 5 half-lives.
- Is an employee of the sponsor company or clinical testing site.
- Is dependent on oral medication for any skin disease/condition or could not, in the opinion of the Investigator tolerate the restriction of discontinuing the medicine as required in this study.
- Is currently pregnant or lactating or planning to become pregnant in the next 6 months (using double contraception for prevention).
- Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation of the results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HAT01H cream
HAT01H medicated cream will come in a blinded tube.
This topical medicated cream will be applied once in the morning and once in the evening at least 8 hours apart to all lesions.
Treatment will continue daily until next visit.
|
HAT01H Cream will be applied twice daily.
The research team will provide instructions for the correct application of the treatment.
If a lesion disappears, patients will continue applying the cream twice daily to the area.
No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Other Names:
|
Placebo Comparator: Vehicle cream
Vehicle cream will come in a blinded tube.
This topical medicated vehicle will be applied once in the morning and once in the evening at least 8 hours apart to all lesions.
Treatment will continue daily until next visit.
|
Vehicle Cream will be applied twice daily.
The research team will provide instructions for the correct application of the treatment.
If a lesion disappears, patients will continue applying the cream twice daily to the area.
No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Scoring of Atopic Dermatitis (SCORAD) score
Time Frame: Baseline to week 12
|
The primary efficacy is determined by absolute change from baseline to week 12 in inflammatory SCORAD.
|
Baseline to week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients achieving a Physician's Global Assessment (PGA) score of 0 or 1
Time Frame: Baseline to week 12
|
The secondary efficacy measures is determined by absolute change from baseline to week 12 in PGA
|
Baseline to week 12
|
Incidence of treatment emergent Adverse Event
Time Frame: Baseline to week 12
|
The secondary efficacy measures also include safety and tolerability (incidence of treatment emergent AE's)
|
Baseline to week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mukta Sachdev, MD, Clinical
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 26, 2017
Primary Completion (Actual)
June 30, 2017
Study Completion (Actual)
July 31, 2017
Study Registration Dates
First Submitted
March 20, 2017
First Submitted That Met QC Criteria
March 20, 2017
First Posted (Actual)
March 24, 2017
Study Record Updates
Last Update Posted (Actual)
November 7, 2018
Last Update Submitted That Met QC Criteria
November 5, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCTP17MD11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eczema
-
Technical University of MunichCelgene CorporationCompletedEczema | Nummular Eczema | Dermatitis Eczema | Nummular DermatitisGermany
-
Odense University HospitalCompletedVesicular Palmoplantar Eczema | PompholyxDenmark
-
Gary GoldenbergCompletedHand Eczema | Foot EczemaUnited States
-
University Hospitals Coventry and Warwickshire...University of WarwickNot yet recruitingCancer | Skin Cancer | Dry Skin; Eczema | Medical Device Site EczemaUnited Kingdom
-
Zealand University HospitalUniversity of Copenhagen; Danish Working Environment FundCompleted
-
SalvatCompleted
-
Incyte CorporationActive, not recruitingHand EczemaUnited States, Poland, Canada, Germany
-
Incyte CorporationWithdrawnHand EczemaUnited States, Germany, Spain, Czechia, Canada, Poland
-
University Hospital Bispebjerg and FrederiksbergStatens Serum InstitutRecruiting
Clinical Trials on HAT01H Cream
-
University of North Carolina, CharlotteTeva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States
-
Incyte CorporationCompletedCutaneous Lichen PlanusUnited States, Canada
-
Incyte CorporationRecruitingPrurigoUnited States, Spain, France, Poland, Germany, Belgium, Netherlands, Argentina, Italy, Canada, Chile, Brazil
-
Edesa Biotech Inc.JSS Medical Research Inc.Active, not recruitingAllergic Contact DermatitisUnited States, Canada
-
LEO PharmaCompletedChronic Hand EczemaUnited States, Germany, Denmark
-
LEO PharmaCompletedHealthy VolunteersGermany
-
LEO PharmaTerminatedDiscoid Lupus ErythematosusUnited States, France, Germany, Denmark
-
Incyte CorporationCompletedHidradenitis SuppurativaUnited States, Canada
-
Incyte CorporationCompletedLichen SclerosusUnited States, Canada
-
Incyte CorporationRecruitingPrurigo NodularisSpain, Korea, Republic of, United States, Poland, Italy, Austria, Germany, Canada, Switzerland, Australia, France, Denmark, Bulgaria